IRVINE, Calif., Nov. 19, 2021 /PRNewswire/ -- Allergan
Aesthetics, an AbbVie company, (NYSE: ABBV) today announced that it
will present six abstracts from its leading portfolio of aesthetic
treatments and products at the American Society for Dermatologic
Surgery (ASDS) meeting taking place virtually November 19-21, 2021.
Allergan Aesthetics' portfolio is one of the most researched
product portfolios across the aesthetic industry. In
continuation of this legacy, our approach to innovative science is
a commitment to bringing new and impactful treatments to our
customers and their patients globally.
"Our science-based findings continue to help drive the
advancement of aesthetic medicine; therefore, we highly value the
opportunity to share our published data with the medical
community," said Darin Messina,
Senior Vice President, Allergan Aesthetics R&D. "We are honored
that the congress is recognizing two BOTOX® Cosmetic
(OnabotulinumtoxinA) abstracts as 'Best of Cosmetic Oral Abstracts'
and look forward to continuing scientific exchange at ASDS in years
to come."
Also being shared at ASDS, Arisa
Ortiz, MD, FAAD, will present product information on
Allergan Aesthetics SkinMedica® TNS®
Advanced+ Serum, Saturday, November
20, from 4:15-5:15 p.m. CT
during one of the Industry Hot Topic sessions.
SkinMedica®'s topical TNS® Advanced+ Serum
for at-home use is comprised of two chambers that work together
when blended to deliver visible results for youthful looking skin.
In a clinical study, at-home topical use of SkinMedica®
TNS® Advanced+ Serum showed visible results in coarse
wrinkles and fine lines in 2 weeks and improved the appearance of
skin discoloration and sagging skin after 8 weeks. Additionally, in
the study, users felt they looked 6 years younger in just 12 weeks,
as assessed by a third-party, validated psychometric
scale.1
Complete abstracts and details on presentation dates and
times can be found on the ASDS website.
Here is the complete list of the accepted six abstracts:
Abstract
|
Perceptions of the
Reduction of Masseter Muscle Prominence Following
OnabotulinumtoxinA Treatment – Fabi S., et al.
Award
Winner: Best of Congress ASDS: "Best of Cosmetic
Oral Abstracts"
|
Canada HARMONY Study:
Comprehensive Panfacial Approach to Aesthetic Treatment, Including
Submental Fullness, Results in Improved Patient-Reported Outcomes –
Bertucci V., et al.
Award
Winner: Best of Congress ASDS: "Best of Cosmetic
Oral Abstracts"
|
Chin Augmentation
with the Hyaluronic Acid Filler VYC-20L Results in High Patient
Satisfaction: A Subgroup Analysis of a Phase 3 Study – Downie J.,
et al.
|
Recently Developed
Hyaluronic Acid Filler VYC-12L Improves Cheek Skin Smoothness:
6-Month Results from a Prospective Study – Alexiades M., et
al.
|
A Prospective,
Open-Label Study to Evaluate Sequential Treatment with ATX-101 and
VYC-20L for Overall Improvement in Jawline Contour – Goodman G., et
al.
|
Neutralizing Antibody
Conversion with OnabotulinumtoxinA from Global Studies Across
Multiple Indications in Nearly 30,000 Patient Records: A
Meta-Analysis – Ogilvie P., et al.
|
1Data on File at SkinMedica®
IMPORTANT SAFETY INFORMATION & APPROVED
USES
BOTOX® Cosmetic may cause serious side
effects that can be life threatening. Get medical help right away
if you have any of these problems any time (hours to weeks) after
injection of BOTOX® Cosmetic:
- Problems swallowing, speaking, or breathing, due to weakening
of associated muscles, can be severe and result in loss of life.
You are at the highest risk if these problems are pre-existing
before injection. Swallowing problems may last for several
months.
- Spread of toxin effects. The effect of botulinum toxin may
affect areas away from the injection site and cause serious
symptoms including: loss of strength and all-over muscle weakness,
double vision, blurred vision and drooping eyelids, hoarseness or
change or loss of voice, trouble saying words clearly, loss of
bladder control, trouble breathing, and trouble swallowing.
BOTOX® Cosmetic dosing units are not the same as,
or comparable to, any other botulinum toxin product. There has
not been a confirmed serious case of spread of toxin effect when
BOTOX® Cosmetic has been used at the recommended dose to
treat frown lines, crow's feet lines, and/or forehead lines.
BOTOX® Cosmetic may cause loss of strength or general
muscle weakness, vision problems, or dizziness within hours to
weeks of taking BOTOX® Cosmetic. If this happens, do not
drive a car, operate machinery, or do other dangerous
activities.
Serious and/or immediate allergic reactions have been
reported. They include: itching, rash, red itchy welts,
wheezing, asthma symptoms, or dizziness or feeling faint. Get
medical help right away if you are wheezing or have asthma
symptoms, or if you become dizzy or faint.
Do not receive BOTOX® Cosmetic if you: are
allergic to any of the ingredients in BOTOX® Cosmetic
(see Medication Guide for ingredients); had an allergic reaction to
any other botulinum toxin product such as Myobloc®
(rimabotulinumtoxinB), Dysport® (abobotulinumtoxinA), or
Xeomin® (incobotulinumtoxinA); have a skin infection at
the planned injection site.
Tell your doctor about all your muscle or nerve
conditions, such as ALS or Lou
Gehrig's disease, myasthenia gravis, or Lambert-Eaton
syndrome, as you may be at increased risk of serious side effects
including difficulty swallowing and difficulty breathing from
typical doses of BOTOX® Cosmetic.
Tell your doctor about all your medical conditions,
including: plans to have surgery; had surgery on your
face; have trouble raising your eyebrows; drooping eyelids; any
other abnormal facial change; are pregnant or plan to become
pregnant (it is not known if BOTOX® Cosmetic can harm
your unborn baby); are breast-feeding or plan to (it is not known
if BOTOX® Cosmetic passes into breast milk).
Tell your doctor about all the medicines you take, including
prescription and over-the-counter medicines, vitamins, and herbal
supplements. Using BOTOX® Cosmetic with certain
other medicines may cause serious side effects. Do not start any
new medicines until you have told your doctor that you have
received BOTOX® Cosmetic in the past.
Tell your doctor if you have received any other botulinum toxin
product in the last 4 months; have received injections of botulinum
toxin such as Myobloc®, Dysport®, or
Xeomin® in the past (tell your doctor exactly which
product you received); have recently received an antibiotic by
injection; take muscle relaxants; take an allergy or cold medicine;
take a sleep medicine; take aspirin-like products or blood
thinners.
Other side effects of BOTOX® Cosmetic
include: dry mouth; discomfort or pain at the injection
site; tiredness; headache; neck pain; and eye problems: double
vision, blurred vision, decreased eyesight, drooping eyelids and
eyebrows, swelling of your eyelids and dry eyes.
APPROVED USES
BOTOX® Cosmetic is a
prescription medicine that is injected into muscles and used to
temporarily improve the look of moderate to severe forehead lines,
crow's feet lines, and frown lines between the eyebrows in
adults.
For more information refer to the Medication Guide or talk with
your doctor.
To report a side effect, please call Allergan at
1-800-678-1605.
Please see BOTOX® Cosmetic full Product Information
including Boxed Warning and Medication Guide.
JUVÉDERM® Injectable Gel Fillers Important
Information
APPROVED USES
JUVÉDERM® VOLUMA™ XC
injectable gel is for deep injection in the cheek area to correct
age-related volume loss and for augmentation of the chin region to
improve the chin profile in adults over 21.
JUVÉDERM® VOLLURE™ XC, JUVÉDERM® Ultra
Plus XC, and JUVÉDERM® Ultra XC injectable gels are for
injection into the facial tissue for the correction of moderate to
severe facial wrinkles and folds, such as nasolabial folds.
JUVÉDERM® VOLLURE™ XC injectable gel is for adults over
21.
JUVÉDERM® VOLBELLA™ XC injectable gel is for
injection into the lips for lip augmentation and for correction of
perioral lines in adults over 21.
JUVÉDERM® Ultra XC injectable gel is for injection
into the lips and perioral area for lip augmentation in adults over
21.
IMPORTANT SAFETY INFORMATION
Are there any reasons why I should not receive any
JUVÉDERM® formulation?
Do not use these products
if you have a history of multiple severe allergies or severe
allergic reactions (anaphylaxis), or if you are allergic to
lidocaine or the Gram-positive bacterial proteins used in these
products.
What precautions should my doctor advise me about?
- Minimize strenuous exercise and exposure to extensive sun or
heat within the first 24 hours following treatment. Exposure to any
of these may cause temporary redness, swelling, and/or itching at
the injection site
- Tell your doctor if you are pregnant or breastfeeding. The
safety of these products for use during pregnancy or while
breastfeeding has not been studied
- The safety of JUVÉDERM® VOLUMA™ XC has not been
studied in patients under 35 years or over 65 years for cheek
augmentation, or under 22 years and over 80 years for chin
augmentation. The safety of JUVÉDERM® VOLLURE™ XC and
JUVÉDERM® VOLBELLA™ XC has not been studied in patients
under 22 years, and the safety of JUVÉDERM® Ultra Plus
XC and JUVÉDERM® Ultra XC has not been studied in
patients under 18 years
- JUVÉDERM® VOLUMA™ XC is intended for use in the chin
and cheek areas. JUVÉDERM® VOLLURE™ XC, JUVÉDERM® Ultra
Plus XC, and JUVÉDERM® Ultra XC are intended for use in
facial wrinkles and folds. JUVÉDERM® VOLBELLA™ XC and
JUVÉDERM® Ultra XC are intended for use in the lips and
perioral area. The safety and effectiveness for treatment in other
areas have not been established in clinical studies
- Tell your doctor if you have a history of excessive scarring
(thick, hard scars) or pigmentation disorders. The safety of
JUVÉDERM® products has not been studied in these
patients and may result in additional scars or changes in
pigmentation
- Tell your doctor if you are on therapy used to decrease the
body's immune response (immunosuppressive therapy). Use may result
in an increased risk of infection
- Tell your doctor before treatment if you are using substances
that can prolong bleeding, such as aspirin, ibuprofen, or other
blood thinners. As with any injection, this may result in increased
bruising or bleeding at the injection site
- Patients who experience skin injury near the site of injection
may be at a higher risk for adverse events
- JUVÉDERM® VOLUMA™ XC was not studied in patients
with significant loose skin of the chin, neck, or jaw
- The effect of JUVÉDERM® VOLUMA™ XC injection into
the chin on facial hair growth has not been studied
What are possible side effects?
The most commonly
reported side effects with JUVÉDERM® injectable gels
included redness, swelling, pain, tenderness, firmness,
lumps/bumps, bruising, discoloration, and itching. For
JUVÉDERM® VOLBELLA™ XC, dryness was also reported. For
JUVÉDERM® VOLUMA™ XC, most side effects resolved within
2 to 4 weeks. For JUVÉDERM® VOLLURE™ XC,
JUVÉDERM® Ultra Plus XC, and JUVÉDERM® Ultra
XC injectable gels, most resolved within 14 days or less. For
JUVÉDERM® VOLBELLA™ XC, most resolved within 30 days or
less. These side effects are consistent with other facial injection
procedures.
Most side effects will resolve with time. Your doctor may choose
to treat side effects persisting over 30 days with antibiotics,
steroids, or hyaluronidase (an enzyme that breaks down hyaluronic
acid).
One of the risks with these products is unintentional injection
into a blood vessel. The chances of this happening are very small,
but if it does happen, the complications can be serious and may be
permanent. These complications, which have been reported for facial
injections, can include vision abnormalities, blindness, stroke,
temporary scabs, or permanent scarring of the skin.
As with all skin injection procedures, there is a risk of
infection.
Visit Juvederm.com or talk to your doctor for more
information. To report a side effect with any JUVÉDERM®
product, please call Allergan at 1-800-433-8871.
Products in the JUVÉDERM® Collection are available
only by a licensed physician or properly licensed practitioner.
APPROVED USE AND IMPORTANT SAFETY INFORMATION
What
is KYBELLA®?
KYBELLA® is a
prescription medicine used in adults to improve the appearance and
profile of moderate to severe fat below the chin (submental fat),
also called "double chin."
It is not known if KYBELLA® is safe and effective for
the treatment of fat outside of the submental area or in children
under 18 years of age.
Who should not receive KYBELLA®?
Do not
receive KYBELLA® if you have an infection in the
treatment area.
Before receiving KYBELLA®, tell your healthcare
provider about all of your medical conditions, including if
you: Have had or plan to have surgery on your face, neck, or
chin; have had cosmetic treatments on your face, neck, or chin;
have had or have medical conditions in or near the neck area; have
had or have trouble swallowing; have bleeding problems; are
pregnant or plan to become pregnant (it is not known if KYBELLA®
will harm your unborn baby); are breastfeeding or plan to
breastfeed (it is not known if KYBELLA® passes into your
breast milk).
Tell your healthcare provider about all the medicines you
take, including prescription and over-the-counter
medicines, vitamins, and herbal supplements. Especially tell your
healthcare provider if you take a medicine that prevents the
clotting of your blood (antiplatelet or anticoagulant
medicine).
What are the possible side effects of
KYBELLA®?
KYBELLA®, can cause
serious side effects, including
- Nerve injury in the jaw (which can cause an uneven smile or
facial muscle weakness)
- Trouble swallowing
- Injection site problems including: a collection of blood under
the skin (hematoma) or bruising, damage to an artery or vein if
KYBELLA® is inadvertently injected into it, hair loss, open sores
(ulcers), damage and tissue cell-death (necrosis) around the
injection site. Call your healthcare provider if you: begin to
develop weakness in the muscles of your face, or your smile becomes
uneven; have difficulty swallowing, or if any of the symptoms that
you already have get worse; develop open sores or drainage from the
treatment area
The most common side effects of
KYBELLA® include swelling, pain,
numbness, redness, and areas of hardness in the treatment area.
These are not all of the possible side effects of
KYBELLA®. Call your doctor for medical advice
about side effects.
Please see KYBELLA® full Prescribing Information.
Please see accompanying full Prescribing Information, or ask your
healthcare provider, or visit MyKybella.com.
SKINMEDICA® IMPORTANT SAFETY INFORMATION
The SkinMedica® product described here is
intended to meet the FDA's definition of a cosmetic product, an
article applied to the human body to cleanse, beautify, promote
attractiveness, and alter appearances. This
SkinMedica® product is not intended to be a drug
product that diagnoses, treats, cures or prevents any disease or
condition. This product has not been approved by the FDA and the
statements on these pages have not been evaluated by the FDA.
For more information, please talk to your provider or visit
SkinMedica.com. To report an adverse reaction, please call
Allergan at 1-800-433-8871.
About Allergan Aesthetics
Allergan Aesthetics, an AbbVie company, develops, manufactures, and
markets a portfolio of leading aesthetics brands and products.
Their aesthetics portfolio includes facial injectables, body
contouring, plastics, skin care, and more. Their goal is to
consistently provide customers worldwide with innovation,
education, exceptional service, and a commitment to excellence, all
with a personal touch.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines
that solve serious health issues today and address the medical
challenges of tomorrow. We strive to have a remarkable impact on
people's lives across several key therapeutic areas: immunology,
oncology, neuroscience, eye care, virology, women's health and
gastroenterology, in addition to products and services across its
Allergan Aesthetics portfolio. For more information about AbbVie,
please visit us at www.abbvie.com. Follow @abbvie on Twitter,
Facebook, Instagram, YouTube and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/allergan-aesthetics-to-present-data-from-its-leading-aesthetic-portfolio-at-the-2021-american-society-for-dermatologic-surgery-virtual-meeting-301426223.html
SOURCE AbbVie